

09/787,657

- 2 -

5947-01-MG

Group IX, claim(s) 17-18, drawn to a screening assay using polypeptides.

Group X, claim(s) 27-29, drawn to polypeptides other than from Group I.

Group XI, claim(s) 30, drawn to antibodies other than from Group VII.

Group XII, claim(s) 31-32, drawn to methods to treat diseases with polynucleotide sequences.


Group XIII, claim(s) 33, drawn to methods to screen for diseases with polynucleotide sequences.

Group XIV, claim(s) 34, drawn to methods of binding of polynucleotides to gabapentin.

The Office Communication further indicates that pursuant to PCT Rule 13.1, restriction to one of Inventions 1-133 is required as they pertain to SEQ ID NO.'s 1-16, 18-41, 43-49 or any one of the sequences not listed as a separate SEQ ID NO in claims 31, 33 or 34.

Applicants hereby elect Group I for prosecution on the merits. Applicants also hereby elect Invention 3 as it pertains to SEQ ID NO:3 for prosecution on the merits. As such, Applicants hereby withdraw from prosecution the claims directed to Groups II-XII and Inventions 1,2, and 4-133 as explained above, without prejudice, and reserve the right to file a Divisional application(s) or any other such appropriate measure to the non-elected claims.

Respectfully submitted,



Mehdi Ganjeizadeh
Reg. No. 47,585
Warner-Lambert Company
2800 Plymouth Road
Ann Arbor, MI 48105
Tel. (734) 622-3831
Fax (734) 622-2928